Related Experiment Video
Updated: Jul 6, 2026

Zebrafish Model of Neuroblastoma Metastasis
Published on: March 14, 2021
MYCN-amplified spinal ependymomas: a rare aggressive subtype. Illustrative cases
Minerva H Zhou1, Soonmee Cha1,2
1Department of Radiology and Biomedical Imaging, University of California, San Francisco, California.
Background:
Spinal ependymomas are typically slow-growing tumors with a favorable prognosis. Recently, a new aggressive subtype has emerged with its own distinct histopathological and molecular features characterized by MYCN amplification. However, this subtype of spinal ependymoma is rare, and studies on its imaging characteristics are limited. In this case series, the authors present the imaging findings of three patients with MYCN-amplified spinal ependymoma from their institution.
Observations:
Unlike typical spinal ependymomas, the MYCN-amplified spinal ependymomas were intradural extramedullary in location in the thoracic and lumbar spine. Imaging revealed T1 isointensity and T2 hyperintensity with avid enhancement and peritumoral edema. The tumor masses were adherent to the spinal cord with filling of the canal and resultant cord compression. There were focal areas without a clear tissue plane between the mass and the cord, which was concerning for cord infiltration. Thus, complete resection was difficult to achieve, and all patients demonstrated residual tumor in the resection bed. Their clinical course was also characterized by early central nervous system (CNS) dissemination, including one case with intracranial involvement.
Lessons:
This case series highlights three instances of MYCN-amplified spinal ependymoma, a rare and aggressive subtype with distinctive imaging features, including an intradural extramedullary location and CNS dissemination at recurrence. https://thejns.org/doi/10.3171/CASE24696.
More Related Videos
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024